Cerity Partners
CHRS icon

Cerity Partners’s Coherus Oncology CHRS Stock Holding History

Cerity Partners’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$104K Buy
74,607
+38,639
+107% +$63.1K ﹤0.01% 3208
2026
Q1 		$60.8K Buy
35,968
+19,375
+117% +$34.4K ﹤0.01% 3088
2025
Q4 		$23.6K Buy
16,593
+2,847
+21% +$4.15K ﹤0.01% 2839
2025
Q3 		$22.5K Buy
13,746
+3,186
+30% +$3.54K ﹤0.01% 2723
2025
Q2 		$7.72K Sell
10,560
-44,116
-81% -$38.1K ﹤0.01% 2624
2025
Q1 		$44.1K Buy
54,676
+24,953
+84% +$28.7K ﹤0.01% 2408
2024
Q4 		$40.2K Sell
29,723
-14,854
-33% -$16.7K ﹤0.01% 2384
2024
Q3 		$46.4K Buy
+44,577
New +$61.1K ﹤0.01% 2489

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Cerity Partners's CHRS Position: Q2 2026 in Review

Cerity Partners increased its Coherus Oncology (CHRS) stake by 107% in Q2 2026, buying an estimated $63.1K and bringing the position to 74,607 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #3208.

Cerity Partners first reported a position in CHRS in Q3 2024 and has held it in 8 quarters since. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Cerity Partners held 74,607 shares of Coherus Oncology worth $104K as of Q2 2026.
  • Cerity Partners bought 38,639 Coherus Oncology shares in Q2 2026, an estimated $63.1K.
  • Coherus Oncology made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #3208 holding.
  • Cerity Partners first reported a position in Coherus Oncology in Q3 2024 and has held it in 8 quarters since.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.